These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34205587)

  • 1. From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin.
    Chen YJ; Chien CS; Chiang CE; Chen CH; Cheng HM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies.
    Yotti R; Seidman CE; Seidman JG
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():129-153. PubMed ID: 30978303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
    Green EM; Wakimoto H; Anderson RL; Evanchik MJ; Gorham JM; Harrison BC; Henze M; Kawas R; Oslob JD; Rodriguez HM; Song Y; Wan W; Leinwand LA; Spudich JA; McDowell RS; Seidman JG; Seidman CE
    Science; 2016 Feb; 351(6273):617-21. PubMed ID: 26912705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
    Shen S; Sewanan LR; Campbell SG
    J Mol Cell Cardiol; 2021 Sep; 158():11-25. PubMed ID: 33992697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin.
    Rohde JA; Roopnarine O; Thomas DD; Muretta JM
    Proc Natl Acad Sci U S A; 2018 Aug; 115(32):E7486-E7494. PubMed ID: 30018063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure.
    Day SM; Tardiff JC; Ostap EM
    J Clin Invest; 2022 Mar; 132(5):. PubMed ID: 35229734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of heart-specific small subunit of myosin light chain phosphatase results in heart failure and conduction disturbance.
    Arimura T; Muchir A; Kuwahara M; Morimoto S; Ishikawa T; Du CK; Zhan DY; Nakao S; Machida N; Tanaka R; Yamane Y; Hayashi T; Kimura A
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1192-H1202. PubMed ID: 29451818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
    Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
    Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to improve cardiac performance: cardiac myosin activators.
    Teerlink JR
    Heart Fail Rev; 2009 Dec; 14(4):289-98. PubMed ID: 19234787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
    Psotka MA; Teerlink JR
    Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.
    Elliott PM
    Cardiovasc Res; 2020 Nov; 116(13):e175-e178. PubMed ID: 33096564
    [No Abstract]   [Full Text] [Related]  

  • 14. SarcTrack.
    Toepfer CN; Sharma A; Cicconet M; Garfinkel AC; Mücke M; Neyazi M; Willcox JAL; Agarwal R; Schmid M; Rao J; Ewoldt J; Pourquié O; Chopra A; Chen CS; Seidman JG; Seidman CE
    Circ Res; 2019 Apr; 124(8):1172-1183. PubMed ID: 30700234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten decreases maximal force and Ca
    Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
    Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.
    Maron MS; Ommen SR
    Circulation; 2021 Mar; 143(12):1181-1183. PubMed ID: 33750209
    [No Abstract]   [Full Text] [Related]  

  • 17. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
    Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
    Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.
    Saberi S; Cardim N; Yamani M; Schulz-Menger J; Li W; Florea V; Sehnert AJ; Kwong RY; Jerosch-Herold M; Masri A; Owens A; Lakdawala NK; Kramer CM; Sherrid M; Seidler T; Wang A; Sedaghat-Hamedani F; Meder B; Havakuk O; Jacoby D
    Circulation; 2021 Feb; 143(6):606-608. PubMed ID: 33190524
    [No Abstract]   [Full Text] [Related]  

  • 19. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
    JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue.
    Sewanan LR; Shen S; Campbell SG
    Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1112-H1123. PubMed ID: 33449850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.